In Q2 2026, Perceptive Advisors held 92 positions worth $6.4B. They initiated 11 new positions and exited 135. Their largest holding was PRAX ($681.6M). Portfolio value grew +26.7% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q2 2026?
Perceptive Advisors held 92 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include PRAX, SYRE, CELC, RYTM, ASND. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q2 2026?
Perceptive Advisors's tracked biotech portfolio was worth $6.4B across 92 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q2 2026?
Perceptive Advisors initiated 11 new positions in Q2 2026, including KARD, AVLN, UNH, ANL, NVCT and 6 more. They also increased 36 existing positions.
What did Perceptive Advisors sell in Q2 2026?
Perceptive Advisors fully exited 135 positions in Q2 2026, including IOVA, GMED, XENE, HTFL, ABBV and 130 more. They also trimmed 26 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisorsportfolio →